Kornimate/medical-research-clean huggingface dataset:
intra-arterial bone-marrow mononuclear cells infusion for acute ischemic stroke

Conditions: Ischemic Stroke

Summary: this trial aims to test that intra-arterial injection of autologous bone marrow mononuclear cells in acute ischemic stroke patients is safe and improves neurological outcomes.

this is a study in which the patients will be included diagnosed of ischemic stroke sharply in the territory of the cerebral average artery that there fulfill criteria of incorporation and none of those of exclusion and that they have signed the informed assent. 76 patients will randomize in proportion 2:1:1 in a group control that will receive only medical conventional treatment and in two groups of intervention that will receive an unique intra-arterial infusion of mononuclear autologous bone marrow stem cells (one group of dose of 2 millions of bmsc for kilogram of weight and another group of dose of 5 millions of bmsc for kilogram of weight). the three groups of patients will be followed for 24 months. the randomization will be stratified depending on the nhss score. this clinical trial has a voluntary substudy to obtain information on plasma biomarkers.

Eligibility criteria:
inclusion criteria: * patients with middle cerebral artery (mca) acute ischemic stroke. * time of stroke onset is known and treatment can be started between day 1 and 7 of onset. * dwi-mri has reliably shown acute mca ischemic lesions * magnetic resonance angiography (mra) must confirm ipsilateral mca permeability * national institute of health stroke scale score of 6-20 at inclusion * age 18-80 years * written informed consent has been obtained exclusion criteria: * hemorrhagic stroke or symptomatic hemorrhagic transformation * lacunar infarction * preocclusive stenosis or total occlusion of ipsilateral carotid artery * worsening of ≥4 points in national institute of health stroke scale in the 24 hours previous to inclusion, attributable to edema or hemorrhagic transformation or suspicious of malignant edema * decrease of consciousness with a glasgow coma scale of \<8 points * patients with present or previous malignant disease during the last 5 years, except for basal cell carcinoma * contraindication for mri or for bone marrow harvest * previous diagnosis of neurodegenerative disease * acute heart failure * hepatic or renal dysfunction (creatinine \>2mg/dl) * coagulopathy * severe co-morbidity * pregnancy, childbearing potential (unless it is certain that pregnancy is not possible) or breast feeding * modified rankin score (mrs) before stroke of ≥2 * participation in any clinical trial in the last 3 months

Keywords: stroke cell therapy bone marrow
evaluation of the effect of different rapid maxillary expansion appliances on airway by acoustic rhinometry

Conditions: Posterior Crossbite, Upper Airway

Summary: rapid maxillary expansion (rme) is an orthodontic treatment based on the principle of opening the midpalatal suture with the effect of orthopedic forces. the aim of this randomized clinical study was to evaluate and compare the effects of tooth-borne, tooth-tissue borne, and bone-borne rapid maxillary expanders on nasal airway by using ar. the null hypothesis was that there is no difference for the effect on nasal airway between the appliances.

introduction: the aim of this 3-arm parallel trial was to compare the effects of tooth-borne (hyrax), tooth tissue-borne (kbme) and bone-borne (midme) rapid maxillary expansion (rme) appliances on nasal airway with acoustic rhinometry (ar). methods: fourty-six 12- to 14-years-old patients with narrow maxilla were randomly allocated into 3 study groups according to the type of rme appliance: tooth-borne, tooth tissue-borne and bone-borne. participants were recruited from the department of orthodontics, faculty of dentistry, izmir katip celebi university, turkey. during the rme treatment, the same protocol was applied to all patients and the expansion screws were activated twice a day (0.4 mm/day). computer-generated randomization was used with group allocation concealed using opaque, sealed envelopes. the outcome assessor was blinded; however, it was not feasible to blind either operator or patients. the primary outcome of this study was the correction of posterior crossbite. secondary outcomes included ar assessment of nasal airway dimensions as nasal volume, the minimal cross-sectional area (mca) 1 and 2. ar measurements were obtained before treatment (t0), after active expansion (t1), and at 3 months-follow-up (t2). one-way analysis of variance (anova) and a bonferroni test was used for inter-group comparison and two-way anova was used for intra-group evalaution.

Eligibility criteria:
inclusion criteria: 1. no previous tonsillar, nasal or adenoid surgery and orthodontic treatment, 2. bilateral crossbite and need for rme, 3. maxillary and mandibular permanent teeth fully erupted, 4. willingness to participate in the study exclusion criteria: 1. the presence of adenotonsillectomy due to tonsillar hypertrophy or adenoidal hypertrophy 2. having nasal/nasopharyngeal /oropharyngeal pathologies, craniofacial syndromes, systemic disease, poor oral hygiene, 3. history of previous orthodontic treatment.

Keywords: rapid maxillary expansion, posterior crossbite, acoustic rhinometry
ghrelin levels in patients with protein c deficiency

Conditions: Protein C Deficiency

Summary: in rodents with protein c deficiency elevated levels of ghrelin has been observed. the purpose of this study is to investigate if patients with protein c deficiency also have elevated levels of ghrelin, and if so, how this affects the patients. 30 patients with protein c deficiency and 30 healthy bmi and gender matched controls are recruited. bloodsamples are taken in order to measure ghrelin and gh levels and other metabolic parameters. the patients and controls are also asked to answer a questionaire regarding appetite. if patients with protein c deficiency have higher levels of ghrelin than the general population, this will lead to new studies that will perhaps help us understand the importance of ghrelin in humans.


Eligibility criteria:
inclusion criteria: * protein c deficiency or healthy subjects * age 18-70 * bmi 18-35 * written statement to join the study exclusion criteria: * chronic illness, apart from protein c deficiency and lifestyle diseases * everyday medication apart from statins, oral diabetes medication and antihypertensive drugs. * blood donation within three months prior to the investigation. * alcohol abuse

Keywords: ghrelin growth hormone protein c deficiency appetite
the effect of digital breast tomosynthesis in breast cancer long-term survival: a single institution study

Conditions: Breast Cancer

Summary: to investigate whether digital breast tomosynthesis (dbt) benefits survival improvement.

to suggest dbt for specific populations, compare the overall survival rate of women with digital mammography (dm) to the dbt screening for women with particular characteristics.

Eligibility criteria:
inclusion criteria: * individuals were diagnosed with breast cancer according to the international disease classification criteria exclusion criteria: * no surgery or incomplete surgical pathology stage * complete remission after neoadjuvant chemotherapy * non-breast cancer death * bilateral breast cancer * male breast cancer * no pre-surgery mammography image

Keywords: breast cancer
the effect of beta-blocker on chronotropic response and cardiorespiratory fitness in patients with atrial fibrillation

Conditions: Atrial Fibrillation

Summary: this is a prospective study to evaluate changes in exercise capacity and chronotropic response to exercise before and after beta-blocker dosage reduction in patients with atrial fibrillation (af).

rate control therapy is the first-line treatment for atrial fibrillation (af). resting heart rate(hr) is the treatment target of rate control therapy in current clinical practice; however, the optimal value for resting heart rate in af remained unclear. beta-blocker(bb) is widely used as rate-control agent. it is concerned that excessive use of bb might lead to a negative effect on exercise capacity in patients with af. the aim of this study is to explore the effect of beta-blocker on hemodynamic parameters and peak oxygen uptake during cardiopulmonary exercise test (cpet).

Eligibility criteria:
inclusion criteria: 1. \> 20 years of age. 2. clinically stable patients with persistent atrial fibrillation using beta-blocker as rate-control agent without dosage adjustment for at least 3 months. 3. resting heart rate \< 80 bpm. 4. left ventricular ejection fraction \> 50%. exclusion criteria: 1. beta-blocker usage due to indications other than rate control for atrial fibrillation. 2. inability to perform a cardiopulmonary exercise testing. 3. presence of contraindications for cardiopulmonary exercise testing according to the american college of sports medicine's guidelines for exercise testing and prescription. 4. patients with implantable cardioverter defibrillator or pacemaker. 5. pregnancy. 6. inability to provide informed consent.

Keywords: atrial fibrillation beta-blocker chronotropic response cardiorespiratory fitness
lifestyle modification in psoriatic patients with fatty liver

Conditions: Psoriasis; Fatty Liver

Summary: several recent reports have shown an increased prevalence of nonalcoholic fatty liver disease (nafld) in those with psoriasis, which may reflect the increased occurrence of metabolic syndrome in this patient population.

the recruitment of 60 fatty live men with chronic disease, psoriasis, will be classified to lifestyle modification group (foe 12 weeks, this patients will take supervised energy or diet restriction program plus their usual immunosuppressive drugs ) and control group will continue their drug program only)

Eligibility criteria:
inclusion criteria: * psoriasis obese patients with coexisting fatty liver * chronic plaque psoriasis * patients who will not show any change in immuno-modulating psoriasis therapies for at least five months before participation in the study. exclusion criteria: * no metabolic syndrome * no renal or cardiac or pulmonary disorders * other types of psoriasis
a clinical trial to investigate the clinical drug-drug interaction of divarasib with probe substrates of p-glycoprotein and breast cancer resistance protein in healthy participants

Conditions: Healthy Participants

Summary: this is a phase 1, open-label, two-period, one-sequence, crossover drug-drug interaction study to assess the p-gp and bcrp inhibition potential of divarasib using digoxin and rosuvastatin as probe substrates, respectively, in healthy participants.


Eligibility criteria:
inclusion criteria: * males or females of non-childbearing potential * within body mass index (bmi) range of 18.0 to 32.0 kg/m2, inclusive exclusion criteria: * significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (gi), neurological, or psychiatric disorder * history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator * poor peripheral venous access
effect of fixed brinzolamide-brimonidine combination on intraocular pressure after phacoemulsification

Conditions: Cataract; Intraocular Pressure

Summary: this study aims to evaluate the effect of fixed brinzolamide-brimonidine combination on intaocular pressure after uncomplicated phacoemulsification surgery. patients scheduled for phacoemulsification will be randomly assigned to 1 of 2 groups. the treatment group will receive 1 drop of brimonidine-brinzolamide fixed combination immediately after surgery, and the control group will receive no treatment. the iop will be measured preoperatively and at 6, 12, and 24 hours postoperatively.

phacoemulsification with the use of an ophthalmic viscosurgical device (ovd) and implantation of a foldable intraocular lens (iol) is the preferred technique for cataract surgery today. ovds in spite of their advantages in phacoemulsification surgery, have been correlated with intraocular pressure (iop) increase within the first 24 hours postoperatively. this constitutes a frequent short-term complication of cataract surgery and can lead to corneal edema and pain. this iop rise may also increase the risk of retinal artery occlusion, ischemic optic neuropathy, and deterioration of preexisting glaucomatous nerve damage. duovisc, an ovd that consists of viscoat (chondroitin sulfate 4.0%-sodium hyaluronate 3.0%) in combination with provisc (sodium hyaluronate 1.0%) is the most frequently used ovd during cataract surgery. to prevent iop spikes postoperatively, various antiglaucoma agents have been used. brinzolamide is a carbonic anhydrase inhibitor that acts upon the ciliary processes and reduces aqueous humor secretion.brimonidine is a highly selective a2-adrenergic agonist that increases uveoscleral outflow and reduces aqueous humor production.

Eligibility criteria:
inclusion criteria: * patients scheduled to undergo cataract surgery by phacoemulsification. exclusion criteria: * previous ocular surgery * ocular hypertension * pseudoexfoliation syndrome * pigment dispersion syndrome * glaucoma * history of severe cardiovascular disease, cerebral or coronary insufficiency, depression, raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans * hypersensitivity to sulfonamides or brimonidine

Keywords: phacoemulsification intraocular pressure cataract brinzolamide brimonidinde fixed combination
the change of bone markers after low dose alendronate in postmenopausal women with bone loss

Conditions: Osteoporosis

Summary: high bone turnover with the bone resorption exceeding bone formation is a major mechanism of postmenopausal osteoporosis. therefore, inhibition of bone resorption is a rational approach for the prevention. the objective of the current study was to determine the short-term efficacy of once-weekly low dose alendronate in the prevention of bone loss in early postmenopausal korean women with moderate bone loss via bone turnover markers. this study was a 12-week, randomized, double-blind clinical trial compared the effects of placebo with alendronate 20 mg once weekly. all subjects received supplemental calcium 600 mg and vitamin d 400 iu daily. fifty two postmenopausal women (the ages between 50-65 year) with lumbar spine bmd at least 2.0 sd below the peak young adult mean were recruited at eulji university hospital, daejeon, korea. bmd was measured by dxa at baseline and serum alkaline phosphatase, osteocalcin and c-terminal telopeptide of type i collagen was measured at baseline and 12 weeks after treatment.


Eligibility criteria:
inclusion criteria: * postmenopausal women (the ages between 50-65 year) with lumbar spine bmd at least 2.0 sd below the peak young adult mean exclusion criteria: * severe osteoporosis * current medication of osteoposis * metabolic bone disease * cancer, stroke etc.

Keywords: osteoporosis alendronate bone marker
drug-drug interaction between rifampicin and progestins/ethinylestradiol and midazolam

Conditions: Biological Availability

Summary: quantify the effect of a probe cyp3a4 inducer (rifampicin) on the pharmacokinetics of levonorgestrel, norethindrone, desogestrel, dienogest, drospirenone,estradiol and midazolam


Eligibility criteria:
inclusion criteria: * healthy female subject based on a complete medical history, physical examination, ecg, and clinical laboratory tests * age: 45 to 70 years (inclusive) at the first screening visit * minimum body weight 50 kg with body mass index (bmi) above or equal to 18.5 kg/m², and below or equal to 30 kg/m² at the first screening visit * postmenopausal state, revealed indicated by either: * medical history, if applicable (natural menopause at least 12 months prior to first study drug administration, for women younger than 60 years confirmed by follicle stimulating hormone (fsh) \>40 iu/l and estradiol ≤ 20 pg/ml; or * surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administration) exclusion criteria: * relevant diseases within the last 4 weeks prior to the first study drug administration, i.e. any disease requiring treatment by a health-care provider * febrile illness within 1 week before the first study drug administration * known severe allergies, non-allergic drug reactions, or multiple drug allergies * presence or history of thrombosis, thrombophlebitis, thromboembolic diseases of veins and/or arteries, e.g. deep vein thrombosis, stroke, myocardial infarction, pulmonary embolism, transient ischemic attack, angina pectoris * presence or history of conditions that increase the risk of thromboembolic diseases, e.g. disturbances of the coagulation system, thromboembolic diseases in close relatives at age ≤50 years\], valvular heart disease, atrial fibrillation, cardiac dysfunction) * presence, history, or suspected presence of malignant tumors or tumors of the liver and pituitary * presence or history of liver disease e.g. disturbances of the bilirubin excretion (dubin-johnson and rotor syndromes), cholecystectomy ; cholestasis, idiopathic icterus or pruritus during a previous pregnancy or estrogen-progestogen treatment * relevant kidney diseases or renal injury associated with multisystem diseases/disorders, e.g. glomerulonephritis systemic lupus erythematous, diabetic nephropathy. a history of a single episode of uncomplicated nephrolithiasis does not prevent participation * known metabolic disorder, e.g. diabetes mellitus, severe hypertriglyceridemia * migraine with neurologic symptoms * clinically significant depression, current or in the last year * known current thyroid disorders which require treatment. subjects with an euthyroid struma who do not need any treatment can participate. * chronic respiratory insufficiency * history of porphyria * contraindications for midazolam, e.g. myasthenia gravis, and sleep apnea
low dose lignocaine injections as a treatment option for acute lumbosacral radiculopathy

Conditions: Pain, Acute

Summary: low back pain is one of the most common ailments that plagues patients, with nearly 80% of the population developing some form of back pain in their lifetime. up regulated sodium channels in the nerve root or dorsal root ganglion are the basic cause for the mechano-sensitization and injecting the drug in the peripheral end of the nerve will block these sodium channels, since functionally both ends of the pseudo unipolar neuron are the same.

low back pain is one of the most common ailments that plague patients, with nearly 80% of the population developing some form of back pain in their lifetime. of all the causes of low back pain, the most common is lumbar radicular pain which may result from irritation of the nerve fibers or dorsal root ganglia due to intervertebral disc prolapse, degenerative spondylolisthesis or spinal canal stenosis. \[1\] up regulated sodium channels in the nerve root or dorsal root ganglion are the basic cause for the mechano-sensitization and injecting the drug in the peripheral end of the nerve will block these sodium channels, since functionally both ends of the pseudo unipolar neuron are the same. \[2\]there have yet been no studies done to prove the efficacy of peripheral nerve block as an alternative to lumbar epidurals. we would like to share our experience of peripheral nerve blocks with low dose local anaesthetics as the treatment of acute lumbosacral radiculopathy.

Eligibility criteria:
inclusion criteria: * age between 18 years to 60 years * pain involving up to two segmental levels (l4, l5 and s1). * average pain score of ≥5 on an 11-point nrs. * tenderness over the concordant peripheral nerves (gore sign +) * computed tomography/magnetic resonance imaging evidence of nerve root pain concordant with the side and level of clinical features. exclusion criteria: * coagulopathy and/or patients on anticoagulants. * infection at the site of injection. * hypersensitivity to a local anaesthetic agent. * evidence of significant sensory or progressive motor deficit. * presence of cancer as a cause of back pain. * history of previous backs surgery/epidural steroid injection.
a comparison between signature total knee arthroplasty (tka) to conventional tka and computer assisted tka

Conditions: Joint Disease

Summary: this is a prospective, randomised clinical outcomes study comparing the signature personalised patient care, conventional total knee arthroplasty and computer assisted navigation, using vanguard knee system. the aim of the study is to evaluate the safety and efficacy of tka using signature personalised patient care compared to conventional tka and computer assisted navigation.

the objective of this study is to report and compare on the outcomes from patients undergoing total knee arthroplasty utilizing 'signaturetm personalised patient care', conventional total knee arthroplasty and computer assisted navigation. the 'signaturetm personalised patient care' is a system that uses a patient's magnetic resonance imaging (mri) and x-ray design to build surgical instruments customized for a patient's unique knee anatomy. cutting positioning guides are produced to match the outer shape of the individual's distal femur and proximal tibia. the cutting positioning guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of total knee replacement components intra-operatively and in guiding the marking of bone before cutting.

Eligibility criteria:
inclusion criteria: * patient is of legal age and skeletally mature * patient requires primary total knee arthroplasty due to non- inflammatory degenerative joint disease (e.g. osteoarthritis, traumatic arthritis, a vascular necrosis, dysplasia/ddh) or inflammatory joint disease (e.g., rheumatoid arthritis). * patient has met an acceptable preoperative medical clearance and is free from or treated for cardiac, pulmonary, haematological, etc., conditions that would pose excessive operative risk * the patient will be available for follow up throughout the duration of the study. exclusion criteria: * patient is unable to have an mri scan due to the following conditions: * cardiac pacemaker * surgical clips in head (aneurysm clips) * some artificial heart valves * electronic inner ear implants * metal fragments in eyes * electronic stimulators * implanted pumps * patient has active infection or sepsis (treated or untreated) * patient has any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery. * patient is female of child-bearing age and not taking contraceptive precautions. * patient has inadequate bone stock to support the device (e.g. severe osteopenia, family history of severe osteoporosis or osteopenia). * patient has known moderate to severe renal insufficiency. * patient has a known or suspected metal sensitivity. * patient is immunosuppressed or receiving high doses of corticosteroids. * patient has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, or drug, alcohol abuse. * patient has bmi \>40.

Keywords: knee arthroplasty